Hrt Financial LP Tyme Technologies, Inc. Transaction History

Hrt Financial LP

  • $18.1 Billion
  • Q3 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.23 - $0.35 $7,734 - $11,770
-33,630 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$0.28 - $0.68 $9,416 - $22,868
33,630 New
33,630 $11,000
Q4 2021

Feb 14, 2022
SELL
$0.6 - $1.04 $58,348 - $101,137
-97,248 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$0.99 - $1.38 $128,987 - $179,800
-130,290 Reduced 57.26%
97,248 $100,000
Q2 2021

Aug 16, 2021
BUY
$1.14 - $1.87 $259,393 - $425,496
227,538 New
227,538 $286,000
Q4 2019

Feb 14, 2020
SELL
$1.0 - $1.49 $41,398 - $61,683
-41,398 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$0.97 - $1.77 $40,156 - $73,274
41,398 New
41,398 $49,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email